Astrocitomas pilomixoides. Presentación de tres casos y revisión de la literatura

Domínguez-Páez, M.; Weil-Lara, B.; Rodríguez-Barceló, S.; Medina-Imbroda, J. M.; Puch-Ramírez, M.; Ros-López, B.; Arráez-Sánchez, M. A.
February 2010
Revista Neurocirugia;feb2010, Vol. 21 Issue 1, p22
Academic Journal
Introduction. Pilomyxoid astrocytoma (PMA) is a central nervous system (CNS) tumour with peculiar clinicopathological features, that turn it into an entity different from pilocytic astrocytoma (PA). It appears in 2007 WHO classification of tumours of the CNS as an PA subtype belonging to the group of astrocytic tumours. Nowadays little is still known about this tumour entity; the histological origin and clinical behavior remain controversial, and there is no consensus about its management. Objective. To review the scientific literature related to the topic and to present three cases treated at our service. Conclusions. PMA is an histological entity related to PA with a greater trend to regrowth and cerebrospinal fluid dissemination, therefore strict follow-up and oncological treatment is recommended.


Related Articles

  • Pilomyxoid astrocytoma in an adult woman: Case report. Kibola, Adam H.; McClelland III, Shearwood; Hlavin, Joseph; Friedman, Jonathan A.; McClelland, Shearwood 3rd // Journal of Cancer Research & Therapeutics;Jul-Sep2015, Vol. 11 Issue 3, Special section p667 

    Pilomyxoid astrocytoma (PMA) is a recently classified WHO grade II astrocytoma that is histologically similar to pilocytic astrocytoma (PA). Both tumors typically present in childhood, but PMA is more aggressive with higher rates of recurrence and cerebrospinal fluid dissemination. Currently,...

  • Low Grade Gliomas in Children. Chalil, Alan; Ramaswamy, Vijay // Journal of Child Neurology;Mar2016, Vol. 31 Issue 4, p517 

    Gliomas represent the most common solid tumor of the nervous system, and can occur as both low and high-grade tumors. Current risk stratification and treatment approaches rely heavily on the morphological classification of gliomas whereby low-grade gliomas have an excellent prognosis,...

  • Proteomic analyses of CSF aimed at biomarker development for pediatric brain tumors. Samuel, Nardin; Remke, Marc; Rutka, James; Raught, Brian; Malkin, David // Journal of Neuro-Oncology;Jun2014, Vol. 118 Issue 2, p225 

    Primary brain tumors cumulatively represent the most common solid tumors of childhood and are the leading cause of cancer related death in this age group. Traditionally, molecular findings and histological analyses from biopsies of resected tumor tissue have been used for diagnosis and...

  • REMOTE IN TIME AND LOCATION MALIGNANT GLIOMA METASTASES TRANSPORTED VIA CEREBROSPINAL FLUID PATHWAYS. A REPORT OF TWO CASES AND LITERATURE REVIEW. Kwiek, S. J.; Bierzynska-Macyszyn, G.; Ślusarczyk, W.; Kukier, W.; Bażowski, P.; Wlaszczuk, P.; Wójcikiewicz, T. // Folia Neuropathologica;2005, Vol. 43 Issue 3, p211 

    This article presents an abstract of the research paper "Remote in Time and Location Malignant Glioma Metastases Transported Via Cerebrospinal Fluid Pathways: A Report of Two Cases and Literature Review," which was discussed in the 13th Conference of the Polish Association of Neuropathologist....

  • Diagnostic value of interleukin-10 in cerebrospinal fluid for diffuse large B-cell lymphoma of the central nervous system. Sasagawa, Yasuo; Akai, Takuya; Tachibana, Osamu; Iizuka, Hideaki // Journal of Neuro-Oncology;Jan2015, Vol. 121 Issue 1, p177 

    A biomarker for early diagnosis of central nervous system (CNS) lymphoma would permit early treatment for attenuation of disease progression and neurological deterioration. High interleukin-10 (IL-10) or an IL-10/IL-6 ratio >1.0 are informative parameters for discriminating intraocular lymphomas...

  • Intracranial malignant melanoma: A report of 7 cases. YUNFENG MA; QIUPING GUI; SENYANG LANG // Oncology Letters;Oct2015, Vol. 10 Issue 4, p2171 

    The aim of the present study was to investigate the clinical diagnosis and treatment of intracranial malignant melanoma. For this purpose, the clinical manifestation, signs, cerebrospinal fluid (CSF) contents, imageology, pathological features, treatment and prognosis of 7 cases of intracranial...

  • Hypoglycorrhachia with Meningeal Carcinomatosis. Kim, Young S.; Resnick, Jerome S. // Annals of Internal Medicine;Jul65, Vol. 63 Issue 1, p115 

    Describes patients with metastatic meningeal carcinomatosis who have positive cerebrospinal fluid (CSF) cytology and low CSF glucose in the absences of central nervous system infection. Overview on medical cases of patients; Neurologic signs; Mechanism by which the lowering of the CSF glucose...

  • The role of chemotherapy in the treatment of patients with brain metastases from solid tumors. Walbert, Tobias; Gilbert, Mark R. // International Journal of Clinical Oncology;Aug2009, Vol. 14 Issue 4, p299 

    Brain metastases are the most frequent cancer in the central nervous system, being ten times more common than primary brain tumors. Patients generally have a poor outcome with a median survival of 4 months after diagnosis of the metastases. Therapeutic options include surgery, stereotactic,...

  • Soft tissue sarcomas and central nervous system tumors in children with neurofibromatosis type 1. Cecen, Emre; Ince, Dilek; Uysal, Kamer; Ozer, Erdener; Cetingoz, Riza; Ozguven, Ali; Cakmakci, Handan; Sarialioglu, Faik; Olgun, Nur // Child's Nervous System;Nov2011, Vol. 27 Issue 11, p1885 

    Objects: We aim to evaluate the characteristics of pediatric patients with neurofibromatosis type 1 (NF1) who developed soft tissue sarcomas (STSs) and central nervous system (CNS) tumors that have been followed up in our center. Materials and methods: Medical records of children with NF1 were...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics